BioSpace News Archive

The Board of Directors of BD has declared a quarterly dividend of $0.91 per common share, payable on March 31, 2023 to holders of record on March 10, 2023.

Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 7, 2023 after the markets close.

Aculys Pharma, Inc. and Four H, Inc. announced an exploratory research collaboration using wearable devices to help patients with narcolepsy and excessive daytime sleepiness associated with obstructive sleep apnea syndrome.

Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan management will participate in the upcoming SVB Securities 2023 Global Biopharma Conference, being held virtually between January 31-February 2 and February 13-16, 2023.

PetDx® – The Liquid Biopsy Company for Pets™ announced that Alejandro Bernal, DVM, MS, MBA, has been appointed as its new President and Chief Executive Officer.

Verastem Oncology (Nasdaq: VSTM) today announces positive interim data from Part A of the ongoing RAMP 201 (ENGOTov60/GOG3052) international registration-directed Phase 2 study evaluating the safety and efficacy of avutometinib (VS-6766) alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer (LGSOC).

Verastem Oncology (Nasdaq:VSTM) today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private placement to raise aggregate gross proceeds of up to approximately $60 million in two tranches, before deducting fees to the placement agent and other estimated offering expenses payable by the Company.

For the families of children battling childhood cancer and other catastrophic diseases, days are often all but typical.

Pliant Therapeutics, Inc., a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, announced the pricing of an upsized underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share.

Precigen, Inc. announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public offering price of $1.75 per share.